An experimental drug aimed at preventing heart attacks and strokes has failed a significant test. This drug was designed to lower levels of a blood particle linked to heart complications. In a recent study, it provided no protection.
Dr. Steven Nissen of the Cleveland Clinic led the research. He expressed his surprise and disappointment at the results. Cardiovascular disease remains a leading cause of death in developed nations. The hope was to find new therapies to reduce this risk.
The study targeted individuals doing everything right to stay healthy. These people maintain low cholesterol and blood pressure, eat well, control their weight, and exercise. Yet, many still suffer from heart issues. Nissen aimed to aid these patients further.
A significant factor is elevated levels of lipoprotein(a) or Lp(a). This cholesterol-related protein increases heart disease risk and affects about 20% of the global population.
Until recently, no drugs could reduce Lp(a) levels. New experimental drugs have emerged to tackle this. Nissen and his team conducted a study with 8,350 heart disease patients. They received either a placebo or a drug called pelacarsen. Pelacarsen reduced Lp(a) levels by about 78%. Yet, this did not lessen cardiovascular complications after five years.
Many in the medical field had high hopes for success. The study’s results were presented at an American Heart Association meeting and published in scientific journals.
Novartis, the drugmaker, sponsored the study and highlighted its significance. They stated that while the study did not meet goals, it offers valuable data about Lp(a) and heart disease.
The drug’s failure to help patients is perplexing. There is speculation about misconceptions regarding Lp(a)’s role in heart disease. Some suggest that longer treatment or a different approach may be necessary.
Experts are also questioning if patients selected for the trial met appropriate criteria. Another possibility is that the drug may only aid those with poorly controlled blood pressure and cholesterol.
Several other companies, such as Amgen and Eli Lilly, are exploring other Lp(a)-lowering drugs. Results from these studies are anticipated in the coming years.
Dr. Karol Watson from UCLA remains optimistic, noting that research into Lp(a) reduction is still in its early stages.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions